相关实验视频
Updated: Mar 3, 2026

05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
5.5K
人环素和心脏:一把双刃剑,有治疗希望
Tariq M Alotaibi1, Ahmad M Samman1, Abdullah A Al Ghamdi1
1King Abdulaziz Medical City, Ministry of National Guard - Health Affairs, Riyadh, Saudi Arabia.
Journal of the Saudi Heart Association
|March 2, 2026
概括
抗环素化疗可能会导致心脏损伤,但几个药物策略显示出预防和管理的希望. 早期,基于风险的干预措施,包括心脏保护疗法,对于保持心脏功能最有效.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 人环素是重要的化疗药物,但它们的使用受到剂量依赖性心脏毒性的限制.
- 这种毒性会导致各种心脏问题,包括心力衰竭和心肌病,影响患者的生存.
- 提高癌症存活率需要解决和减轻因人环素引起的心脏损伤.
研究的目的:
- 审查当前对人类环素诱导心脏毒性机制的理解.
- 评估现有和新兴的药理学策略,以预防和管理这种不良影响.
主要方法:
- 进行了全面的文献搜索,直到2025年8月.
- 关键来源包括随机对照试验,元分析,观察性研究和指南陈述.
- 专注于药理干预措施,以减轻antracycline心脏毒性.
主要成果:
- 心脏毒性机制包括氧化应激,线粒体功能障碍,DNA损伤和失调.
- 神经激素调节剂 (ACE抑制剂,ARBs,β-阻断剂) 提供适度的益处,而螺旋龙则显示出有效性.
- 萨库比特里尔/瓦尔沙坦显示有前途;代谢调节剂和他类药物具有潜在的益处,而德克斯拉佐被批准用于预防.
结论:
- 多种药理学策略可以帮助限制环素心脏毒性并保持心脏功能.
- 个性化,基于风险的方法整合早期心脏保护疗法是最有希望的.
- 需要进一步的大规模随机试验来优化治疗组合并确认长期益处.
相关概念视频
Heart Failure Drugs: Inotropic Agents
1.7K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
2.1K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
2.7K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.7K
Heart Failure Drugs: β-Blockers
1.0K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K
Cardiovascular Drugs: Classification based on Therapeutic Indications
4.4K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.4K

